樂普醫療(300003.SZ)股東科技投資公司擬減持不超400萬股
格隆匯8月16日丨樂普醫療(300003.SZ)公佈,持公司股份約3516.67萬股(佔公司總股本比例1.97%)的股東中船重工科技投資發展有限公司(科技投資公司)計劃在2019年通過深圳證券交易系統以集中競價交易的方式減持公司股份不超過400萬股(含),佔公司總股本比例不超過0.22%,佔公司剔除已回購股份後的股本比例不超過0.23%(以截至2019年7月31日公司累計回購股份約1240.28萬股為依據計算)。
科技投資公司與公司股東中國船舶重工集團第七二五研究所同受中國船舶重工集團公司控制,其合計持有超過5%以上的公司股份,屬於公司持股5%以上股東。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.